News

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.27 per share was significantly above analysts’ consensus estimates.

Gaming products and services provider Light & Wonder (NASDAQ:LNW) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 3.5% year on year to $797 million. Its GAAP profit of $1.20 per share was 23.4% above analysts’ consensus estimates.

Super Micro stock rallied late Tuesday after it met a deadline to submit its delayed SEC filings in order to avoid delisting by the Nasdaq.

Civil infrastructure construction company Sterling Infrastructure (NASDAQ:STRL) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 2.6% year on year to $498.8 million. On the other hand, the company’s full-year revenue guidance of $2.08 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 10% above analysts’ consensus estimates.

Financial and compliance reporting software company Workiva (NYSE:WK) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 19.9% year on year to $199.9 million. The company expects next quarter’s revenue to be around $204 million, close to analysts’ estimates. Its non-GAAP profit of $0.33 per share was in line with analysts’ consensus estimates.

Major U.S. equities indexes were mixed after a weak consumer confidence report and losses from several noteworthy tech firms.

Luxury electric car manufacturer Lucid (NASDAQ:LCID) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 49.2% year on year to $234.5 million. Its GAAP loss of $0.22 per share was 15.7% above analysts’ consensus estimates.

Medical tech company Masimo (NASDAQ:MASI) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.4% year on year to $600.7 million. Its non-GAAP profit of $1.80 per share was 26.3% above analysts’ consensus estimates.

Traders are getting concerned about froth in the market, according to a new survey from Schwab.

Medical device company Merit Medical Systems (NASDAQ:MMSI) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.4% year on year to $355.2 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.93 per share was 12.2% above analysts’ consensus estimates.